Apellis Pharmaceuticals (APLS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

For the quarter ended December 2025, Apellis Pharmaceuticals, Inc. (APLS) reported revenue of $199.91 million, down 5.9% over the same period last year. EPS came in at $0.47, compared to -$0.29 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $194.37 million, representing a surprise of +2.85%. The company delivered an EPS surprise of +219.14%, with the consensus EPS estimate being -$0.40.While investors scrutinize revenue and earnings changes year-over-year and how th ...